Aripiprazole for ongoing symptoms after infection
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Infections, Lungs & breathing, Mental health clinical trials.
This study tests whether a medication called aripiprazole can help with long-lasting symptoms like brain fog, fatigue, or mood changes that start after an infection (such as COVID-19). It aims to see if this treatment improves these neuropsychiatric symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have had a confirmed or suspected infection (like COVID-19) in the past.
- You must have had symptoms for at least 3 months after the infection.
- You must be experiencing symptoms like brain fog, fatigue, or mood changes at the start of the study.
- You must not have certain other conditions (like severe psychiatric illness, cancer, or a chronic neurological disease).
- You must not be taking antipsychotic medication or be allergic to aripiprazole.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a treatment that removes certain immune cells (called B cells) can help people with ME/CFS (chronic fatigue syndrome) that started after an infection. It is for people who have already tried a procedure called immunoadsorption and felt better but then got worse again.
This Phase 2/3 trial studies whether anakinra can improve ongoing (post-acute) COVID-19 symptoms lasting for more than two months. It mainly looks for better safety and symptom improvement in people with specific inflammation and lung-related findings.
This study tests whether a commonly used drug (repurposed) can help improve Long COVID symptoms like fatigue, breathing problems, or brain fog. It is for adults 18 to 65 who had COVID-19 in the past 4 years and still have symptoms after 3 months.
This study tests whether a drug called pembrolizumab, which helps the immune system, can reduce long-lasting nervous system symptoms from COVID-19 (often called long COVID). It is for people who have had symptoms like fatigue, brain fog, or dizziness for at least 6 months after a mild or moderate COVID infection.
This study uses a special PET scan to look at inflammation in the body of people with long COVID (symptoms lasting 3+ months after infection). The goal is to understand why symptoms persist and find better ways to help.
This study tests whether a lab-made antibody (sipavibart) can reduce Long COVID symptoms. It is for people who developed Long COVID after a confirmed COVID infection and still have moderate to severe fatigue and other ME/CFS-like symptoms.
Hear when a new Post-acute Infectious Syndrome (PAIS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.